Lombard Odier Asset Management USA Corp Buys New Stake in Stryker Corporation (SYK), Report finds

Lombard Odier Asset Management USA Corp Buys New Stake in Stryker Corporation (SYK), Report finds

Lombard Odier Asset Management USA Corp bought a new stake in Stryker Corporation (NYSE:SYK) during the third quarter, Holdings Channel reports. The firm bought 12,900 shares of the medical technology company’s stock, valued at approximately $1,502,000.

Several other hedge funds also recently added to or reduced their stakes in the company. Putnam FL Investment Management Co. raised its stake in Stryker Corporation by 77.1% in the second quarter. Putnam FL Investment Management Co. now owns 55,030 shares of the medical technology company’s stock valued at $6,594,000 after buying an additional 23,953 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank raised its stake in Stryker Corporation by 26.6% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 58,994 shares of the medical technology company’s stock valued at $7,069,000 after buying an additional 12,408 shares during the period. Ngam Advisors L.P. raised its stake in Stryker Corporation by 217.3% in the second quarter. Ngam Advisors L.P. now owns 77,132 shares of the medical technology company’s stock valued at $9,243,000 after buying an additional 52,821 shares during the period. Pillar Pacific Capital Management LLC raised its stake in Stryker Corporation by 11.1% in the second quarter. Pillar Pacific Capital Management LLC now owns 30,803 shares of the medical technology company’s stock valued at $3,691,000 after buying an additional 3,078 shares during the period. Finally, BB&T Corp raised its stake in Stryker Corporation by 998.4% in the second quarter. BB&T Corp now owns 39,509 shares of the medical technology company’s stock valued at $4,734,000 after buying an additional 35,912 shares during the period. 75.58% of the stock is currently owned by institutional investors.

Shares of Stryker Corporation (NYSE:SYK) traded down 0.08% during midday trading on Wednesday, reaching $122.41. The company’s stock had a trading volume of 689,562 shares. Stryker Corporation has a 52-week low of $95.67 and a 52-week high of $127.23. The stock has a market cap of $45.84 billion, a price-to-earnings ratio of 28.14 and a beta of 0.80. The stock has a 50-day moving average price of $121.47 and a 200-day moving average price of $116.29.

Stryker Corporation (NYSE:SYK) last issued its earnings results on Tuesday, January 24th. The medical technology company reported $1.78 earnings per share for the quarter, beating the consensus estimate of $1.76 by $0.02. The company earned $3.20 billion during the quarter, compared to analysts’ expectations of $3.15 billion. Stryker Corporation had a return on equity of 23.86% and a net margin of 14.54%. Stryker Corporation’s quarterly revenue was up 16.3% compared to the same quarter last year. During the same period in the prior year, the business posted $1.56 EPS. Equities research analysts anticipate that Stryker Corporation will post $6.41 earnings per share for the current fiscal year.

The firm also recently declared a quarterly dividend, which will be paid on Friday, April 28th. Shareholders of record on Friday, March 31st will be given a dividend of $0.425 per share. This represents a $1.70 dividend on an annualized basis and a yield of 1.39%. The ex-dividend date is Wednesday, March 29th. Stryker Corporation’s payout ratio is 39.08%.

Several analysts recently weighed in on SYK shares. Wells Fargo & Company reaffirmed an “outperform” rating and issued a $134.50 price objective on shares of Stryker Corporation in a research note on Saturday, January 28th. Canaccord Genuity raised their price objective on Stryker Corporation from $127.00 to $137.00 and gave the company a “buy” rating in a research note on Monday, January 23rd. Needham & Company LLC reaffirmed a “sell” rating on shares of Stryker Corporation in a research note on Wednesday, January 25th. Barclays PLC raised their price objective on Stryker Corporation from $120.00 to $122.00 and gave the company an “underweight” rating in a research note on Wednesday, January 25th. Finally, Jefferies Group LLC raised their price objective on Stryker Corporation from $120.00 to $132.00 and gave the company a “hold” rating in a research note on Wednesday, January 25th. Two analysts have rated the stock with a sell rating, eight have assigned a hold rating and thirteen have issued a buy rating to the company. The stock presently has a consensus rating of “Hold” and a consensus price target of $125.75.

In other Stryker Corporation news, Director Louise Francesconi sold 3,716 shares of the company’s stock in a transaction that occurred on Monday, January 30th. The stock was sold at an average price of $122.34, for a total transaction of $454,615.44. Following the completion of the transaction, the director now owns 20,242 shares of the company’s stock, valued at approximately $2,476,406.28. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Ronda E. Stryker sold 5,194 shares of the company’s stock in a transaction that occurred on Wednesday, December 28th. The shares were sold at an average price of $120.60, for a total value of $626,396.40. Following the transaction, the director now directly owns 193,142 shares of the company’s stock, valued at approximately $23,292,925.20. The disclosure for this sale can be found here. Insiders have sold a total of 230,570 shares of company stock valued at $26,547,517 in the last ninety days. 7.80% of the stock is currently owned by corporate insiders.

Stryker Corporation Company Profile

Stryker Corporation (Stryker) is a medical technology company. The Company operates through three segments: Orthopaedics, MedSurg, and Neurotechnology and Spine. The Company’s Orthopaedics segment products consist of implants used in hip and knee joint replacements and trauma and surgeries. The Company’s MedSurg segment products consist of surgical equipment and surgical navigation systems (Instruments); endoscopic and communications systems (Endoscopy); patient handling and emergency medical equipment (Medical), and reprocessed and remanufactured medical devices (Sustainability), as well as other medical device products used in a range of medical specialties.

Want to see what other hedge funds are holding SYK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Stryker Corporation (NYSE:SYK).

Related posts

Leave a Comment

Lombard Odier Asset Management USA Corp Buys New Stake in Stryker Corporation (SYK)

Lombard Odier Asset Management USA Corp Buys New Stake in Stryker Corporation (SYK)

Lombard Odier Asset Management USA Corp bought a new stake in Stryker Corporation (NYSE:SYK) during the third quarter, Holdings Channel reports. The firm bought 12,900 shares of the medical technology company’s stock, valued at approximately $1,502,000.

Several other hedge funds also recently added to or reduced their stakes in the company. Putnam FL Investment Management Co. raised its stake in Stryker Corporation by 77.1% in the second quarter. Putnam FL Investment Management Co. now owns 55,030 shares of the medical technology company’s stock valued at $6,594,000 after buying an additional 23,953 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank raised its stake in Stryker Corporation by 26.6% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 58,994 shares of the medical technology company’s stock valued at $7,069,000 after buying an additional 12,408 shares during the period. Ngam Advisors L.P. raised its stake in Stryker Corporation by 217.3% in the second quarter. Ngam Advisors L.P. now owns 77,132 shares of the medical technology company’s stock valued at $9,243,000 after buying an additional 52,821 shares during the period. Pillar Pacific Capital Management LLC raised its stake in Stryker Corporation by 11.1% in the second quarter. Pillar Pacific Capital Management LLC now owns 30,803 shares of the medical technology company’s stock valued at $3,691,000 after buying an additional 3,078 shares during the period. Finally, BB&T Corp raised its stake in Stryker Corporation by 998.4% in the second quarter. BB&T Corp now owns 39,509 shares of the medical technology company’s stock valued at $4,734,000 after buying an additional 35,912 shares during the period. 75.58% of the stock is currently owned by institutional investors.

Shares of Stryker Corporation (NYSE:SYK) traded down 0.08% during midday trading on Wednesday, reaching $122.41. The company’s stock had a trading volume of 689,562 shares. Stryker Corporation has a 52-week low of $95.67 and a 52-week high of $127.23. The stock has a market cap of $45.84 billion, a price-to-earnings ratio of 28.14 and a beta of 0.80. The stock has a 50-day moving average price of $121.47 and a 200-day moving average price of $116.29.

Stryker Corporation (NYSE:SYK) last issued its earnings results on Tuesday, January 24th. The medical technology company reported $1.78 earnings per share for the quarter, beating the consensus estimate of $1.76 by $0.02. The company earned $3.20 billion during the quarter, compared to analysts’ expectations of $3.15 billion. Stryker Corporation had a return on equity of 23.86% and a net margin of 14.54%. Stryker Corporation’s quarterly revenue was up 16.3% compared to the same quarter last year. During the same period in the prior year, the business posted $1.56 EPS. Equities research analysts anticipate that Stryker Corporation will post $6.41 earnings per share for the current fiscal year.

The firm also recently declared a quarterly dividend, which will be paid on Friday, April 28th. Shareholders of record on Friday, March 31st will be given a dividend of $0.425 per share. This represents a $1.70 dividend on an annualized basis and a yield of 1.39%. The ex-dividend date is Wednesday, March 29th. Stryker Corporation’s payout ratio is 39.08%.

Several analysts recently weighed in on SYK shares. Wells Fargo & Company reaffirmed an “outperform” rating and issued a $134.50 price objective on shares of Stryker Corporation in a research note on Saturday, January 28th. Canaccord Genuity raised their price objective on Stryker Corporation from $127.00 to $137.00 and gave the company a “buy” rating in a research note on Monday, January 23rd. Needham & Company LLC reaffirmed a “sell” rating on shares of Stryker Corporation in a research note on Wednesday, January 25th. Barclays PLC raised their price objective on Stryker Corporation from $120.00 to $122.00 and gave the company an “underweight” rating in a research note on Wednesday, January 25th. Finally, Jefferies Group LLC raised their price objective on Stryker Corporation from $120.00 to $132.00 and gave the company a “hold” rating in a research note on Wednesday, January 25th. Two analysts have rated the stock with a sell rating, eight have assigned a hold rating and thirteen have issued a buy rating to the company. The stock presently has a consensus rating of “Hold” and a consensus price target of $125.75.

In other Stryker Corporation news, Director Louise Francesconi sold 3,716 shares of the company’s stock in a transaction that occurred on Monday, January 30th. The stock was sold at an average price of $122.34, for a total transaction of $454,615.44. Following the completion of the transaction, the director now owns 20,242 shares of the company’s stock, valued at approximately $2,476,406.28. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Ronda E. Stryker sold 5,194 shares of the company’s stock in a transaction that occurred on Wednesday, December 28th. The shares were sold at an average price of $120.60, for a total value of $626,396.40. Following the transaction, the director now directly owns 193,142 shares of the company’s stock, valued at approximately $23,292,925.20. The disclosure for this sale can be found here. Insiders have sold a total of 230,570 shares of company stock valued at $26,547,517 in the last ninety days. 7.80% of the stock is currently owned by corporate insiders.

Stryker Corporation Company Profile

Stryker Corporation (Stryker) is a medical technology company. The Company operates through three segments: Orthopaedics, MedSurg, and Neurotechnology and Spine. The Company’s Orthopaedics segment products consist of implants used in hip and knee joint replacements and trauma and surgeries. The Company’s MedSurg segment products consist of surgical equipment and surgical navigation systems (Instruments); endoscopic and communications systems (Endoscopy); patient handling and emergency medical equipment (Medical), and reprocessed and remanufactured medical devices (Sustainability), as well as other medical device products used in a range of medical specialties.

Want to see what other hedge funds are holding SYK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Stryker Corporation (NYSE:SYK).

Related posts

Leave a Comment